Sharula et al. [59] have proposed SYB to be a promising therapeutic compound for liver cancer as they found that SYB inhibited cell proliferation and promoted cell apoptosis mainly through miR-34a/P53/caspase-9 axis in HepG2 cells, demonstrating the clinical application value of SYB in liver cancer treatment. The gene discussed is TP53; the disease is liver cancer.